MicuRx Pharmaceuticals is based in Shanghai, China. It has raised $150M in total funding. Latest round: IPO.
MicuRx Pharmaceuticals funding overview
MicuRx Pharmaceuticals is based in Shanghai, China. MicuRx Pharmaceuticals has raised $150M in total disclosed funding. That places its disclosed total in the $100M–$250M range. Its most recent disclosed round is an IPO announced in August 2022. The round record for MicuRx Pharmaceuticals runs through 2022; nothing later has been disclosed. Investors on record include BVCF, Morningside Group, Devon Park Bioventures. 3 distinct backers are named across the disclosed rounds.
MicuRx Pharmaceuticals at a glance
Total raised
$150M
Latest round
IPO
Latest round date
August 2022
Headquarters
Shanghai, China
Notable investors
BVCF, Morningside Group, Devon Park Bioventures
Frequently asked about MicuRx Pharmaceuticals funding
How much has MicuRx Pharmaceuticals raised?
MicuRx Pharmaceuticals has raised $150M in total disclosed funding across the rounds on record.
Who has invested in MicuRx Pharmaceuticals?
BVCF, Morningside Group, Devon Park Bioventures are named among the investors backing MicuRx Pharmaceuticals.
What was the latest MicuRx Pharmaceuticals funding round?
The most recent disclosed round is an IPO, announced in August 2022.
Where is MicuRx Pharmaceuticals based?
MicuRx Pharmaceuticals is based in Shanghai, China.
When did MicuRx Pharmaceuticals last raise?
The last disclosed MicuRx Pharmaceuticals round closed in August 2022 at IPO.
Every MicuRx Pharmaceuticals figure above comes from filings and announced rounds in the StartupFundraising company database and is revised as new rounds are recorded. The lists below compare companies in Shanghai at a similar stage.
